Tango falls after wider-than-expected quarterly loss
11/08/2026 16:18
BUZZ-Tango falls after wider-than-expected quarterly loss ** Shares of drug developer Tango Therapeutics TNGX.O fall 3.3% to $26.75
** Co reports Q2 loss of 37 cents/share, vs. analysts' average loss estimate of 31 cents/share, according to LSEG data
** TNGX reported no collaboration revenue for the three months ended June 30, 2026, citing the end of partnership and research activities with Gilead GILD.O
** It had recorded collaboration revenue of $3.2 million for the same period in 2025
** In June, TNGX said its drug vopimetostat, when tested in combination with Revolution Medicines' RVMD.O daraxonrasib, shrank tumors in 11 of 12 patients with a type of pancreatic cancer that was previously treated
** Including session's moves, stock has more than tripled YTD
(Reporting by Christy Santhosh)
Recent news on Tango Therapeutics
See all newsBrief: Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Tango Therapeutics - Files Prospectus To Sell Up To $400 Million In Common Stock
U.S. STOCKS ON THE MOVEX-Abbott, Columbia Financial, Jabil
U.S. STOCKS ON THE MOVEX-Abbott, Columbia Financial, Jabil,
Tango falls after wider-than-expected quarterly loss